Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zimmer Biomet Holdings (XSWX:ZBH) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Zimmer Biomet Holdings Forward PE Ratio Related Terms
Zimmer Biomet Holdings Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zimmer Biomet Holdings Forward PE Ratio Chart
Zimmer Biomet Holdings Annual Data
Trend
2015-12
2016-12
2017-12
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
13.66
11.76
14.41
12.82
17.73
17.27
14.20
16.72
14.62
14.43
11.92
Zimmer Biomet Holdings Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
13.66
11.90
14.18
14.37
11.76
13.95
14.75
12.79
14.41
14.79
14.20
16.21
12.82
15.85
14.99
16.95
17.73
13.50
29.67
16.98
17.27
21.10
22.27
15.22
14.20
18.38
18.08
15.75
16.72
17.61
17.01
14.71
14.62
13.77
15.06
14.81
14.43
14.70
16.49
10.44
11.92
10.71
XSWX:ZBH vs STE, PEN, GMED: Forward PE Ratio Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings Forward PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's Forward PE Ratio falls into.
Zimmer Biomet Holdings Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Zimmer Biomet Holdings (XSWX:ZBH) has a Forward PE Ratio of 10.85 as of Jul. 14, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Zimmer Biomet Holdings and its competitors. According to the industry distribution chart, Zimmer Biomet Holdings ranks #74 out of 392 companies in the Medical Devices & Instruments industry, placing it in the top 18.9%.
Is Zimmer Biomet Holdings' Forward PE Ratio too high?
Zimmer Biomet Holdings' current Forward PE Ratio is 10.85. The Medical Devices & Instruments industry median Forward PE Ratio is 19.09. Zimmer Biomet Holdings' value of 10.85 is 43.2% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #74 out of 392 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Forward PE Ratio compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #74 out of 392 companies for Forward PE Ratio. This places Zimmer Biomet Holdings in the top 19% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 19.09. Zimmer Biomet Holdings' value of 10.85 is 43.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 19.09, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current Forward PE Ratio of 10.85 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 19.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current Forward PE Ratio is 10.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Forward PE Ratio of 10.85. The stock's GF Value™ is CHF102.70, compared to a current price of CHF76.50 — trading 25.5% below its estimated fair value. The current Forward PE Ratio is 10.85 and 43.2% below the Medical Devices & Instruments industry median of 19.09. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Forward PE Ratio is 10.85 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF76.50 is trading 25.5% below its estimated GF Value™ of CHF102.70.
Key valuation signals for XSWX:ZBH:
Forward PE Ratio: 10.85
GF Value™: CHF102.70 vs. price of CHF76.50 (25.5% below fair value)
Industry Position: 43.2% below the Medical Devices & Instruments median (#74 of 392)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score
Get the complete analysis for XSWX:ZBH
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
